Raia Drogasil S.A. (BVMF:RADL3)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 42.86B |
| Revenue (ttm) | 44.25B |
| Net Income (ttm) | 1.30B |
| Shares Out | 1.75B |
| EPS (ttm) | 0.78 |
| PE Ratio | 31.37 |
| Forward PE | 24.74 |
| Dividend | 0.38 (1.55%) |
| Ex-Dividend Date | Dec 8, 2025 |
| Volume | 14,306,500 |
| Average Volume | 9,844,215 |
| Open | 24.23 |
| Previous Close | 24.53 |
| Day's Range | 23.60 - 24.80 |
| 52-Week Range | 12.81 - 27.42 |
| Beta | 0.16 |
| RSI | 39.20 |
| Earnings Date | Mar 3, 2026 |
About Raia Drogasil
Raia Drogasil S.A. engages in the retail sale of medicines, perfumes, personal hygiene and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. It sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil. [Read more]
Financial Performance
In 2025, Raia Drogasil's revenue was 44.25 billion, an increase of 13.84% compared to the previous year's 38.87 billion. Earnings were 1.30 billion, an increase of 8.08%.
Financial StatementsNews
Raia Drogasil S.A. (RADLY) Q3 2025 Earnings Call Transcript
Raia Drogasil S.A. (OTCPK:RADLY) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Renato Raduan - CEO & Member of Executive Board Flavio de Correia - Director of Investor Relati...
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative retu...
Raia Drogasil: Valuation Burn Now, Healthy Gains Later
Raia Drogasil, Brazil's top pharmacy chain, has consistently delivered robust growth with an 18% CAGR in both revenue and profit over the last decade. Despite Brazil's macroeconomic challenges, the co...